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Abstract
Background: Mycoplasma sp. 1220 can induce inflammation primarily in the genital and respiratory tracts of
waterfowl, leading to serious economic losses. Adequate housing and appropriate antibiotic treatment are
promoted in the control of the disease. The aim of the present study was to determine the in vitro susceptibility to
thirteen different antibiotics and an antibiotic combination of thirty-eight M. sp. 1220 strains isolated from geese
and a duck in several parts of Hungary, Central Europe between 2011 and 2015.
Results: High MIC50 values were observed in the cases of tilmicosin (>64 μg/ml), oxytetracycline (64 μg/ml),
norfloxacin (>10 μg/ml) and difloxacin (10 μg/ml). The examined strains yielded the same MIC50 values with
spectinomycin, tylosin and florfenicol (8 μg/ml), while enrofloxacin (MIC50 5 μg/ml), doxycycline (MIC50 5 μg/ml),
lincomycin (MIC50 4 μg/ml) and lincomycin-spectinomycin (1:2) combination (MIC50 4 μg/ml) inhibited the growth
of the bacteria with lower concentrations. Tylvalosin (MIC50 0.5 μg/ml) and two pleuromutilins (tiamulin MIC50 0.
625 μg/ml; valnemulin MIC50 ≤ 0.039 μg/ml) were found to be the most effective drugs against M. sp. 1220.
However, strains with elevated MIC values were detected for all applied antibiotics.
Conclusions: Valnemulin, tiamulin and tylvalosin were found to be the most effective antibiotics in the study.
Increasing resistance was observed in the cases of several antibiotics. The results highlight the importance of
testing Mycoplasma species for antibiotic susceptibility before therapy.
Keywords: Antibiotic resistance, Duck, Goose, MIC, Microbroth dilution, Mycoplasma sp. 1220
Abbreviations: MIC, Minimal inhibitory concentrations
Background
Mycoplasma sp. 1220 was first described as a new
Mycoplasma species by Stipkovits et al. in 1986 [1]. This
Mycoplasma species causes cloaca and phallus inflam-
mation and testicular atrophy in the ganders [1, 2]. In
the infected geese salpingitis and vaginitis are the
main symptoms [1, 3]. The egg production activates
the pathogen and the flared up mycoplasmosis could
induce lethal pathological changes in the embryos [1, 4].
Airsacculitis and peritonitis are also common, and general
symptoms such as changes in thirst, decreased food con-
sumption, body weight losses, weakness, nasal discharge,
impaired breathing, conjunctivitis, diarrhoea and nervous
signs were also described in the affected waterfowl flocks
[2, 5–8]. Mycoplasma infection of the birds can aggravate
diseases caused by other agents and could lead to serious
economic losses [3, 6]. Since there is no commercially
available vaccine against M. sp. 1220, adequate housing
and appropriate antibiotic treatment are promoted in the
control of the diseases caused by this agent. Prophylactic
medication could prevent economic losses if appropriate
antibiotics are administered in the early weeks of life and
in expected stress periods. Medication of the layers is
essential to reduce the vertical transmission of M. sp.
1220 [2].
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Mycoplasmas are resistant to β-lactam antimicrobials
because of the lack of cell-wall and the bacteria are also
resistant to membrane synthesis inhibitors [2, 9]. Antibi-
otics such as quinolones, tetracyclines, macrolides and
pleuromutilins which induce DNA fragmentation or in-
hibition at the level of protein synthesis are the drugs of
choice for the therapy of mycoplasmosis. Among the
macrolides, erythromycin showed high effectiveness
against Mycoplasma strains which could ferment glucose
(e.g. M. sp. 1220), while arginine-hydrolysing strains proved
to be less susceptible to this compound [2, 10]. Myco-
plasma infected waterfowl and poultry flocks are usually
treated with macrolides, pleuromutilins or with the com-
bination of lincomycin and spectinomycin [3, 11–18].
The aim of this study was to determine the susceptibility
of 38 Hungarian M. sp. 1220 isolates to thirteen anti-
biotics and a drug combination using the microbroth
dilution method.
Methods
A total of 38M. sp. 1220 strains isolated from geese and
a duck originating from different parts of Hungary were
tested in the study (Table 1, Fig. 1). The samples were
collected during routine diagnostic examinations or nec-
ropsies between 2011 and 2015, thus ethical approval
was not required for the study. Phallus lymph, cloaca
swabs, tracheal swabs, follicules and lung samples were
washed in 2 ml of Mycoplasma broth medium (pH 7.8)
(ThermoFisher Scientific Inc./Oxoid Inc./, Waltham, MA)
supplemented with 0.5 % (w/v) sodium pyruvate, 0.5 %
(w/v) glucose and 0.005 % (w/v) phenol red and incubated
at 37 °C in a 5 % CO2 atmosphere. The cultures were in-
oculated onto solid Mycoplasma media (Thermo Fisher
Scientific Inc./Oxoid Inc./) after colour change of the
broth, and were incubated at 37 °C and 5 % CO2 until vis-
ible colonies appeared (1–2 days). Purification of mixed
cultures was performed by one-time filter cloning, minim-
izing the in vitro mutations of the isolates. The QIAamp
DNA Mini Kit (Qiagen Inc., Hilden, Germany) was used
for DNA extraction according to the manufacturers’ in-
structions for Gram-negative bacteria. The purity of the
cultures was confirmed by a universal Mycoplasma PCR
system targeting the 16S/23S rRNA intergenic spacer
region in Mycoplasmatales followed by sequencing on
an ABI Prism 3100 automated DNA sequencer (Applied
Biosystems, Foster City, CA), sequence analysis and
BLAST search [19]. The number of colour changing units
(CCU) was calculated by microbroth dilution method,
from the lowest dilution showing colour change after one
week of incubation [9].
The following antimicrobial agents were examined
during the microbroth dilution tests: the fluoroquino-
lones: enrofloxacin (batch SZBA336XV), difloxacin
(SZBD178XV) and norfloxacin (batch SZBD099XV);
the aminoglycoside: spectinomycin (batch SZBB166XV);
the lincosamide: lincomycin (batch SZBC340XV); the tet-
racyclines: doxycycline (batch SZBD007XV) and oxytetra-
cycline (batch SZBC320XV); the macrolides: tilmicosin
(batch SZBC345XV) and tylosin (batch SZBB160XV);
the pleuromutilins: tiamulin (batch SZBC026XV) and
valnemulin (batch SZBE127XV); and the phenicol: florfe-
nicol (batch SZBC223XV); all products originated from
VETRANAL, Sigma-Aldrich, Germany. The macrolide
tylvalosin (Aivlosin, ECO Animal Health Ltd., UK; LOT
M102A) was also included in the examinations. Lincomy-
cin and spectinomycin were applied also in combination
at a ratio of 1:2. The antibiotics were diluted and stored
according to the recommendations of Hannan [9]. Stock
solutions of 1 mg/ml fluoroquinolones were prepared in
0.1 M NaOH; stock solution of 1 mg/ml florfenicol was
prepared in 96 % ethanol and in sterile distilled water; and
the rest of the stock solutions of 1 mg/ml were prepared
in sterile distilled water. Dilutions of the antibiotics were
freshly prepared for each microtest from the aliquots
stored at −70 °C. Twofold dilutions were prepared in the
range 0.039–10 μg/ml for fluoroquinolones, doxycycline
and pleuromutilins, 0.25–64 μg/ml for spectinomycin,
lincomycin, lincomycin-spectinomycin (1:2) combination,
oxytetracycline and macrolides and 0.125–32 μg/ml for
florfenicol.
The microbroth dilution examinations on 104–105 CCU/
ml of the strains were performed according to Hannan [9].
Mycoplasma broth medium was used in the tests as well,
and each 96-well microtiter plates contained growth con-
trols (broth medium without antibiotic), sterility controls
(broth medium without antibiotic and Mycoplasma inocu-
lum) and pH controls (broth medium adjusted to pH 6.8).
One clinical isolate (strain MYCAV 65) was selected to be
used as quality control of minimal inhibitory concentration
(MIC) determination throughout the experiments. The
duplicates of three clinical isolates and the duplicate of
the selected strain (MYCAV 65) were tested on each 96-
well microtiter plates.
The MIC values were determined from the lowest con-
centration of the antibiotics where no pH and colour
change of the broth was detected after one week of incu-
bation, meaning that the growth of the bacteria was
completely inhibited in the broth. MIC50 and MIC90
values were defined as the lowest concentrations that
inhibited the growth of 50 % or 90 % of the strains [9].
Results
The quality control strain (MYCAV 65) showed consist-
ent results throughout the study. Strains with elevated
MIC values were found in the cases of all tested antibi-
otics (Tables 1 and 2).
Among the fluoroquinolones, the MIC values of enro-
floxacin and difloxacin showed a wide range (1.25 to
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Table 1 Background data and MIC values of the isolated Mycoplasma sp. 1220 strains
MIC values (μg/ml)
Fluoroquinolones Aminoglycoside Lincosamide
Sample ID Sample source Place Animal Date Enrofloxacin Norfloxacin Difloxacin Spectinomycin Lincomycin Lincomycin-
spectinomycin
(1:2) combination
MYCAV 65 Phallus lymph Rém goose 2014 5 >10 10 16 4 4
MYCAV 34 Phallus lymph Szentes goose 2011 5 >10 10 8 4 2
MYCAV 35 Phallus lymph Rém goose 2012 5 >10 10 >64 4 4
MYCAV 36 Cloaca Hajdúböszörmény goose 2012 5 >10 >10 64 4 4
MYCAV 38 Cloaca Kelebia goose 2012 2.5 >10 10 8 2 4
MYCAV 44 Cloaca Nagykamarás goose 2012 5 >10 10 8 4 4
MYCAV 47 Lung Tázlár duck 2012 >10 >10 >10 16 >64 16
MYCAV 49 Phallus lymph Tiszavasvári goose 2013 5 >10 10 16 4 4
MYCAV 50 Phallus lymph Cered goose 2013 >10 >10 >10 16 4 4
MYCAV 51 Phallus lymph Derekegyház goose 2013 5 >10 10 32 4 4
MYCAV 53 Phallus lymph Szentes goose 2013 5 >10 10 16 4 4
MYCAV 54 Follicule Hódmezővásárhely goose 2013 5 >10 10 8 4 4
MYCAV 55 Follicule Kiskunmajsa goose 2013 10 >10 10 8 4 4
MYCAV 56 Phallus lymph Sükösd goose 2013 1.25 >10 1.25 8 4 4
MYCAV 59 Follicule Rém goose 2013 5 >10 10 8 4 4
MYCAV 61 Phallus lymph Tatárszentgyörgy goose 2013 5 >10 10 16 2 4
MYCAV 63 Trachea Sükösd goose 2013 1.25 10 1.25 8 2 2
MYCAV 66 Phallus lymph Tiszaföldvár goose 2014 5 >10 10 16 4 4
MYCAV 67 Phallus lymph Szentes goose 2014 5 >10 10 8 >64 16
MYCAV 68 Phallus lymph Érpatak goose 2014 5 >10 10 8 >64 32
MYCAV 69 Phallus lymph Ludas goose 2014 5 >10 10 4 4 4
MYCAV 70 Phallus lymph Cered goose 2014 >10 >10 >10 16 4 4
MYCAV 71 Phallus lymph Sükösd goose 2014 1.25 >10 1.25 8 2 4
MYCAV 72 Phallus lymph Nagykamarás goose 2014 5 >10 10 8 4 4
MYCAV 75 Phallus lymph Dömsöd goose 2014 5 >10 10 16 4 4
MYCAV 76 Phallus lymph Tiszabábolna goose 2014 5 >10 10 32 8 4
MYCAV 91 Phallus lymph Hajdúsámson goose 2011 10 >10 >10 8 8 4
MYCAV 93 Phallus lymph Bojt goose 2014 2.5 >10 1.25 8 2 4
MYCAV 94 Cloaca Tiszabábolna goose 2012 2.5 >10 5 16 4 4
MYCAV 160 Phallus lymph Érpatak goose 2015 >10 >10 >10 16 4 4
MYCAV 161 Phallus lymph Szilaspogony goose 2015 >10 >10 >10 8 4 4
MYCAV 162 Phallus lymph Encsencs goose 2015 2.5 >10 10 8 4 4
MYCAV 176 Phallus lymph Cered goose 2015 10 >10 5 8 4 4
MYCAV 177 Phallus lymph Cered goose 2015 >10 >10 10 8 4 4
MYCAV 178 Follicule Cered goose 2015 5 >10 10 8 2 4
MYCAV 179 Trachea Apátfalva goose 2015 10 >10 10 16 4 4
MYCAV 180 Phallus lymph Kisbér goose 2015 5 >10 10 >64 4 4
MYCAV 202 Cloaca Kelebia goose 2015 5 >10 5 16 4 4
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>10 μg/ml), while all strains had very high MIC values
for norfloxacin (≥10 μg/ml) (Fig. 2a, b and c). The
MIC50 was 8 μg/ml for spectinomycin and most of the
strains yielded the MIC50 or higher MIC values (Fig. 2d).
The MICs for lincomycin clustered around the MIC50
value (4 μg/ml) as well, but high MIC values (>64 μg/ml)
were yielded in the case of three isolates (Fig. 2e). The
MIC50 and the MIC90 values (4 μg/ml) for lincomycin-
spectinomycin (1:2) combination was the same as the
MIC50 value for lincomycin. In the case of lincomycin-
MIC values (μg/ml)
Tetracyclines Macrolides Pleuromutilines Phenicol
Sample ID Oxytetracycline Doxycycline Tylosin Tilmicosin Tylvalosin Tiamulin Valnemulin Florfenicol
MYCAV 65 32 5 0.5 0.5 ≤0.25 1.25 0.078 8
MYCAV 34 64 2.5 1 4 ≤0.25 0.625 ≤0.039 4
MYCAV 35 64 10 1 4 ≤0.25 1.25 ≤0.039 8
MYCAV 36 64 >10 1 4 ≤0.25 1.25 ≤0.039 8
MYCAV 38 4 0.156 ≤0.25 ≤0.25 ≤0.25 0.625 ≤0.039 4
MYCAV 44 8 0.312 8 >64 0.5 1.25 ≤0.039 8
MYCAV 47 >64 5 16 >64 1 2.5 0.312 8
MYCAV 49 64 5 8 >64 0.5 0.625 ≤0.039 8
MYCAV 50 >64 5 2 2 ≤0.25 0.625 ≤0.039 8
MYCAV 51 >64 10 8 >64 0.5 0.625 ≤0.039 8
MYCAV 53 >64 10 8 >64 0.5 0.625 ≤0.039 8
MYCAV 54 >64 5 8 >64 0.5 0.625 ≤0.039 8
MYCAV 55 8 0.312 ≤0.25 ≤0.25 ≤0.25 0.625 ≤0.039 4
MYCAV 56 4 0.312 8 >64 0.5 0.625 ≤0.039 4
MYCAV 59 32 2.5 0.5 ≤0.25 ≤0.25 1.25 0.078 2
MYCAV 61 2 0.078 ≤0.25 ≤0.25 ≤0.25 0.312 ≤0.039 4
MYCAV 63 4 0.312 4 64 ≤0.25 0.156 ≤0.039 4
MYCAV 66 >64 >10 ≤0.25 ≤0.25 ≤0.25 0.625 ≤0.039 4
MYCAV 67 >64 5 >64 >64 16 2.5 0.078 4
MYCAV 68 >64 10 >64 >64 16 5 ≤0.039 8
MYCAV 69 >64 5 8 >64 1 0.625 ≤0.039 4
MYCAV 70 >64 >10 16 >64 1 0.625 ≤0.039 8
MYCAV 71 8 0.625 8 >64 0.5 0.625 ≤0.039 4
MYCAV 72 4 0.312 8 >64 0.5 0.625 ≤0.039 4
MYCAV 75 >64 10 ≤0.25 ≤0.25 ≤0.25 0.625 ≤0.039 8
MYCAV 76 64 5 8 >64 0.5 1.25 ≤0.039 8
MYCAV 91 64 2.5 ≤0.25 ≤0.25 ≤0.25 0.625 ≤0.039 8
MYCAV 93 8 0.312 ≤0.25 ≤0.25 ≤0.25 0.312 ≤0.039 8
MYCAV 94 >64 >10 ≤0.25 ≤0.25 ≤0.25 0.625 ≤0.039 8
MYCAV 160 >64 10 >64 >64 2 0.625 ≤0.039 8
MYCAV 161 >64 >10 16 >64 0.5 0.625 ≤0.039 8
MYCAV 162 >64 5 16 >64 0.5 0.625 ≤0.039 4
MYCAV 176 >64 5 64 >64 4 0.625 ≤0.039 16
MYCAV 177 >64 10 >64 >64 4 0.625 ≤0.039 32
MYCAV 178 >64 5 4 >64 0.5 0.312 ≤0.039 4
MYCAV 179 4 0.312 4 4 0.5 1.25 ≤0.039 8
MYCAV 180 4 0.312 32 >64 1 1.25 ≤0.039 8
MYCAV 202 32 2.5 0.5 0.5 ≤0.25 1.25 ≤0.039 8
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spectinomycin (1:2) combination the highest concentration
needed for inhibition was 32 μg/ml (Fig. 2f). Broad ranges
of the MIC values were observed for tetracyclines (2 to
>64 μg/ml for oxytetracycline and 0.078 to >10 μg/ml for
doxycycline) with high MIC50 and MIC90 values (Fig. 2g
and h). The broadest ranges of MIC values were detected
for tylosin and tilmicosin (≤0.25 to >64 μg/ml) with high
MIC50 and MIC90 values in the case of tilmicosin (Fig. 2i
and j). While the MIC values for tylosin showed diverse dis-
tribution, the strains’ susceptibility profiles formed three
groups in the case of tilmicosin (≤0.25, 4 and >64 μg/ml)
(Fig. 2j). Among the examined three macrolides (tylosin,
tilmicosin and tylvalosin), tylvalosin showed the lowest
MIC50 value (0.5 μg/ml) against the strains (Fig. 2k). From
the pleuromutilins the MIC values of tiamulin were higher
than those of valnemulin, and the latter compound was
found to be the most active antibiotic in the examinations
(Fig. 2l and m). In the case of florfenicol, the susceptibility
profiles of most strains were similar to each other and
showed the MIC50 and MIC90 value (8 μg/ml) or its two-
fold lower dilution (4 μg/ml) with few exceptions (Fig. 2n).
M. sp. 1220 strains isolated year by year from the same
farms and from the same tissue types (e.g. strains
MYCAV 34, 53 and 67 from Szentes, strains MYCAV
50, 70, 176 and 177 from Cered, or strains MYCAV 38
and 202 from Kelebia) showed elevated MIC values from
50 km
n=1
n=2
n=3
n=5
Fig. 1 Map of Hungary showing the geographical origin of the Mycoplasma sp. 1220 isolates. Size of the circles indicates the number (n) of the
strains. (The blank map was downloaded from an open source [28])
Table 2 Summary of MIC range, MIC50 and MIC90 values of the
isolated Mycoplasma sp. 1220 strains
Antibiotic class Antibiotic agent Range MIC50 MIC90
Fluoroquinolones Enrofloxacin 1.25 to >10 5 >10
Norfloxacin 10 to >10 >10 >10
Difloxacin 1.25 to >10 10 >10
Aminoglycoside Spectinomycin 4 to >64 8 32
Lincosamide Lincomycin 2 to >64 4 8
Lincomycin-
spectinomycin (1:2)
combination
2 to 32 4 4
Tetracyclines Oxytetracycline 2 to >64 64 >64
Doxycycline 0.078 to >10 5 >10
Macrolides Tylosin ≤0.25 to >64 8 >64
Tilmicosin ≤0.25 to >64 >64 >64
Tylvalosin ≤0.25 to 16 0.5 4
Pleuromutilins Tiamulin 0.156 to 5 0.625 1.25
Valnemulin ≤0.039 to 0.312 ≤0.039 0.078
Phenicol Florfenicol 2 to 32 8 8
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Fig. 2 MIC distribution of test antibiotics against Mycoplasma sp. 1220 isolates
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year to year in the cases of certain antibiotics. Higher
MIC values were detected in subsequent isolates for
lincomycin, lincomycin-spectinomycin combination, tetra-
cyclines (both oxytetracycline and doxycycline), macro-
lides (tylosin, tilmicosin and tylvalosin), tiamulin and for
florfenicol as well.
Discussion
Information about the susceptibility of M. sp. 1220 strains
to antimicrobials is scarce, as until to date the sole pub-
lished reference concerning the antibiotic susceptibility
profile of this species is a review of Stipkovits and Szathm-
ary [3]. Stipkovits and Szathmary determined the values of
enrofloxacin, tylosin, chlortetracycline, oxytetracycline,
doxycycline, tiamulin and lincomycin in Mycoplasma spe-
cies affecting waterfowl (M. anatis, M. cloacale, M. anseris
and M. sp. 1220), although detailed data of their method
is lacking [3]. Thus we are facing the absence of reports
about the antibiotic susceptibility of M. sp. 1220 and also
of other Mycoplasma species occurring in waterfowl.
Therefore, the results of the current study are also
compared to data of antibiotic susceptibility of the well-
studied Mycoplasma species of poultry: M. synoviae and
M. gallisepticum.
Elevated MIC values were reported previously in the
case of the fluoroquinolones, especially of enrofloxacin
in M. sp. 1220 (MIC50 2 μg/ml and MIC90 4 μg/ml) and
other Mycoplasma species of poultry [3, 13, 20, 21]. In
addition, the increasing occurrence of quinolone-
resistant M. synoviae and M. gallisepticum field isolates
were also observed [13, 22]. In the current study, the de-
tected MIC50 values (5 μg/ml for enrofloxacin, 10 μg/ml
for difloxacin and ≥10 μg/ml for norfloxacin) were even
higher than the ones reported before [3, 13, 20–22], con-
firming the observation of increasing quinolone-resistance
in Mycoplasma species. In order to save these antibiotics
for human disease treatment the directive was to reduce
the use of these agents in livestock. Former efforts for the
prevention of the appearance of quinolone-resistant
species are proved to be unsuccessful considering the ob-
served dramatic elevations in the MIC values of these an-
tibiotics in avian Mycoplasma species [13, 21, 23].
Administration of the combination of lincomycin and
spectinomycin could reduce the egg infertility rates
and increase the hatching rates and the egg production
in M. sp. 1220 infected geese [11]. The lincomycin-
spectinomycin therapy was proved to be effective against
other Mycoplasma species as well; however, application of
spectinomycin in monotherapy is not recommended for
its insufficient effectiveness and relatively high MIC values
in in vitro experiments [12]. In vitro effectiveness of linco-
mycin at 2 μg/ml MIC50 values against M. sp. 1220, M.
anseris and M. anatis species has been reported [3]. In the
present study, all isolates showed elevated MIC values for
spectinomycin, lincomycin and lincomycin-spectinomycin
combination. The growth of a couple of strains was
not inhibited even at the highest concentrations used
(64 μg/ml) for spectinomycin and lincomycin individually.
The combination of the two antibiotics improved their
effectiveness, as lincomycin-spectinomycin combination
could inhibit the growth of all examined strains within the
concentration range used (0.25 to 64 μg/ml) and lower
MIC90 value was observed also.
Previously, tetracyclines (chlortetracycline, doxycycline
and oxytetracycline) showed 1–2 μg/ml MIC values against
M. sp. 1220 strains. Growth of other Mycoplasma species
isolated from waterfowl were inhibited at 2–4 μg/ml
MIC50 values using the same antibiotics [3]. Previously
Mycoplasma species infecting poultry were observed to be
inhibited by elevated MIC values, although with excep-
tions, as M. synoviae strains showed high susceptibility to
doxycycline in the Netherlands [12–14]. In the current
study, although the M. sp. 1220 strains showed broad
ranges of MIC values for oxytetracycline and doxycycline,
more than 50 % of the strains were inhibited by only higher
antibiotic concentrations (64 and 5 μg/ml, respectively)
and MIC90 values exceeded the concentration ranges used
for both compounds. These results show a dramatic
increase of the MIC values of tetracyclines against M.
sp. 1220 strains and reveals the presence of probably
highly resistant strains in Hungary.
Macrolides, especially tylvalosin have good in vitro ef-
fectiveness against most Mycoplasma species infecting
poultry, showing lower MIC values in previous examina-
tions than quinolones and tetracyclines [3, 12–15]. How-
ever, M. gallisepticum could develop resistance rapidly
to these compounds, especially to tilmicosin [24]. Earlier,
the MIC50 values in M. sp. 1220, M. anatis, M. anseris
and M. cloacale strains were defined to be 2 μg/ml for
tylosin [3]. In the current study, the MIC50 value (8 μg/
ml) of tylosin was higher than the previous observation
[3], and the MIC90 value exceeded the concentration
range used in the experiment. However, high variability
was observed in the susceptibility of the strains to this
compound. Similarly, wide range of the MIC values was
detected for tilmicosin, highlighting the necessity of sus-
ceptibility testing before antibiotic treatments. As op-
posed to the diverse susceptibility profiles of the strains
for tylosin, the MIC values of tilmicosin were catego-
rized into three separate groups. The observed distribu-
tion of the MIC values is likely in association with the
capability of Mycoplasma sp. 1220 to develop resistance
more rapidly to tilmicosin (i.e. with one or two muta-
tions) than to other macrolides. The same phenomenon
was described in other Mycoplasma species as well
[24]. Out of the three macrolides examined in the
study, tylvalosin proved to be the most effective agent
against M. sp. 1220 strains, showing lower MIC50 value
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(0.5 μg/ml) against the pathogen than the majority of
the antibiotics tested.
Pleuromutilins showed good in vitro effectiveness
against avian Mycoplasma species in previous studies
and low tendency of the development of resistance to
these agents has been reported [16–18, 21]. Tiamulin
was used successfully for the treatment of mycoplasmo-
sis and its effectiveness was similar to spectinomycin
therapy in the treated geese [11]. Stipkovits and Szathm-
ary described low MIC values (MIC50: 0.06 μg/ml,
MIC90: 0.25 μg/ml) of tiamulin in the case of M. sp.
1220, and similarly low MIC50 values (0.125–1 μg/ml)
were observed against M. anseris, M. anatis and M.
cloacale [3]. In the present study, pleuromutilins were
found to be the most effective antibiotic agents and the
examined compounds, especially valnemulin showed
high in vitro effectiveness against all tested isolates of
the pathogen. However, it is noteworthy, that strains
with elevated MIC values were detected for tiamulin
(MIC: 2.5–5 μg/ml) and even for valnemulin (MIC:
0.312 μg/ml). Although the low MIC values of valnemulin
against M. sp. 1220 strains in vitro are promising for its
clinical use, it should be noted that in a previous study
only a single mutation in M. gallisepticum could cause ele-
vation in the MIC values of valnemulin [17]. To date, the
use of pleuromutilins in humans is limited, as only one
commercially available product is authorized containing
this active substance. However, bacterial strains resistant
to pleuromutilins have already been described and these
strains also show multidrug resistance, which warrants the
prudent use of these antibiotic agents [25].
Phenicols showed good in vitro activity against Myco-
plasma species of poultry, but information about their
effectiveness in waterfowl is lacking [26, 27]. In the
present study, most of the M. sp. 1220 isolates yielded
the same MIC values (4 or 8 μg/ml) for florfenicol, and
only two isolates (originating from the same region)
showed elevated MIC values compared to the MIC50
(8 μg/ml), one of them reaching the highest antibiotic
concentration (32 μg/ml) used.
The elevated MIC values of several antibiotics detected
in subsequent isolates from the same farms from year
to year are likely in association with the inconsistent
use of antibiotics, the rapid development of antibiotic
resistance and highlight the importance of susceptibility
testing before therapy and responsible use of antimicrobial
drugs.
Conclusion
In the present examinations the antibiotic susceptibility
profiles of thirty-eight M. sp. 1220 strains isolated in
Hungary were determined. To the best of our know-
ledge, this is the first detailed study about the antibiotic
susceptibility of M. sp. 1220, a pathogen which could
cause significant economic losses in waterfowl flocks.
Valnemulin, tiamulin and tylvalosin were found to be
the most effective antibiotics in the present study. Most
of the isolates showed elevated MIC values for more
than one agent, but none of the strains yielded high
MIC values for all the examined antibiotics. Neverthe-
less, our results confirmed that increasing resistance
could be observed in the cases of several antibiotics.
These findings highlight the consistent use of antibiotics
and the need for determination of antibiotic susceptibil-
ity of Mycoplasma species before treatment.
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